Pliant Therapeutics (PLRX) Competitors $1.53 -0.06 (-3.77%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.14 (+9.22%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. ERAS, ITOS, SLDB, ATXS, NBTX, FULC, CGEM, KMDA, INBX, and AURAShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Erasca (ERAS), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Cullinan Therapeutics (CGEM), Kamada (KMDA), Inhibrx Biosciences (INBX), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Erasca iTeos Therapeutics Solid Biosciences Astria Therapeutics Nanobiotix Fulcrum Therapeutics Cullinan Therapeutics Kamada Inhibrx Biosciences Aura Biosciences Pliant Therapeutics (NASDAQ:PLRX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Which has more risk and volatility, PLRX or ERAS? Pliant Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PLRX or ERAS? 97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 14.4% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is PLRX or ERAS more profitable? Erasca's return on equity of -31.19% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -73.45% -55.66% Erasca N/A -31.19%-26.34% Does the media favor PLRX or ERAS? In the previous week, Erasca had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 5 mentions for Erasca and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 1.82 beat Erasca's score of 0.84 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Pliant Therapeutics Very Positive Erasca Positive Do analysts rate PLRX or ERAS? Pliant Therapeutics currently has a consensus price target of $8.19, suggesting a potential upside of 435.13%. Erasca has a consensus price target of $3.71, suggesting a potential upside of 132.14%. Given Pliant Therapeutics' higher possible upside, research analysts clearly believe Pliant Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.08Erasca 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher earnings and valuation, PLRX or ERAS? Erasca has lower revenue, but higher earnings than Pliant Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M59.45-$210.30M-$3.40-0.45ErascaN/AN/A-$161.65M-$0.45-3.56 SummaryErasca beats Pliant Therapeutics on 8 of the 13 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.61M$3.11B$5.75B$10.24BDividend YieldN/A2.32%5.69%4.60%P/E RatioN/A21.3874.9326.41Price / Sales59.45224.82452.3586.56Price / CashN/A44.4425.8129.91Price / Book0.319.6413.256.28Net Income-$210.30M-$53.20M$3.29B$270.38M7 Day Performance-11.56%0.44%0.47%2.70%1 Month Performance-1.29%4.26%4.60%5.99%1 Year Performance-87.25%9.43%73.42%25.94% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.1099 of 5 stars$1.53-3.8%$8.19+435.1%-86.8%$97.61M$1.58M0.0090Positive NewsGap UpERASErasca2.3694 of 5 stars$1.55-3.7%$3.71+139.6%-47.5%$456.71MN/A-3.44120Analyst DowngradeITOSiTeos Therapeutics3.4493 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences2.9305 of 5 stars$5.13-6.7%$15.00+192.4%-32.0%$428.28M$8.09M-1.83100Positive NewsAnalyst DowngradeATXSAstria Therapeutics2.8503 of 5 stars$7.43-1.2%$29.00+290.3%-33.3%$424.39MN/A-3.7030Positive NewsNBTXNanobiotix0.6362 of 5 stars$8.71+0.1%$8.00-8.2%+96.0%$417.11M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑FULCFulcrum Therapeutics2.6176 of 5 stars$7.27-5.1%$7.57+4.1%+120.1%$414.34M$80M-5.96100News CoveragePositive NewsShort Interest ↓CGEMCullinan Therapeutics2.2014 of 5 stars$6.84-2.1%$26.80+291.8%-63.6%$412.93MN/A-2.1230Analyst ForecastKMDAKamada4.5476 of 5 stars$7.22+1.1%$13.00+80.1%+28.6%$410.59M$169.52M21.24360Short Interest ↓INBXInhibrx Biosciences1.0624 of 5 stars$29.10+3.3%N/A+67.7%$408.20M$200K-2.75166Positive NewsAURAAura Biosciences2.2411 of 5 stars$6.47-0.2%$22.00+240.0%-38.6%$402.54MN/A-3.3050 Related Companies and Tools Related Companies ERAS Alternatives ITOS Alternatives SLDB Alternatives ATXS Alternatives NBTX Alternatives FULC Alternatives CGEM Alternatives KMDA Alternatives INBX Alternatives AURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts